Discovered nearly thirty years ago in 1988, stem cell technology has failed to transform the field of regenerative medicine…until now. After delivering only one treatment during three decades of development, stem cell technology could finally become the all-purpose tool for repairing the body, thanks to rapid and precise genome editing techniques such as CRISPR and TALENs. Several obstacles in stem cell technology- high costs, safety concerns, and bioethical considerations – are beginning to fall away. In particular, the introduction of induced pluripotent stem cells (iPSCs) eliminated many of the initial bioethical concerns stirred by the the source of stem cells. Now, advances in genome-editing are accelerating the pace of progress.
Stem cells exist in a “state of possibility”. Two key markers of stem cells are 1) the ability to self-renew and 2). The ability to become any specialized cell. Broadly speaking, a stem cell can evolve into any of the ~200 specialized human cell types, as illustrated in Figure 1. Directing stem cells to become any one of the 200 cell types has proven challenging.
Moreover, before the introduction of iPSCs, which are derived from adult cells, most human stem cells were sourced from human embryos or cord blood. The political and ethical controversies surrounding embryonic research curtailed stem cell funding. As a result, after a quarter century of research, bone marrow transplantation is the only FDA-approved stem cell application in the United States.
Breakthroughs in cheap, rapid genome-editing have re-invigorated momentum in stem cell research. As shown in Figure 2, the number of publications on PubMed mentioning both stem cells and gene-editing hit a tipping point upon the discovery of CRISPR in 2012, three years after the first instance of precise TALENs-based genome-editing in human cells. Based on the current trajectory, ARK estimates that the number of scientific publications including both genome-editing and stem cells will approach 300 this year, accounting for nearly 20% of the total number of publications.
As illustrated in Figure 3, while the discovery of iPSC cells in 2006 boosted stem cell research noticeably beginning in 2008, the introduction of CRISPR in 2012 has further catapulted the stem cell field, with combined gene-editing and stem cell publications taking share.
Why Is The Addition of Gene-Editing So Important to Stem Cell Research and Therapy?
- Enhanced Safety Profile: CRISPR-edited stem cell therapies should offer a safer class of therapeutics than any other technology. While CRISPR technology is often criticized for off-target effects, they occur less frequently in iPSCs than in other cells lines.– Moreover, with stem cell therapy alone, patients have to undergo chemotherapy, suffering dangerous side effects. CRISPR-edited stem cell therapy eliminates the need for chemotherapy, while mitigating off-target effects.
- Higher Efficiency and Lower Costs: iPSC cells spontaneously transform into more specialized cells, often making labwork quite difficult. With a shorter editing turnaround time, CRISPR lowers the probability that iPSCs differentiate into mature cells before the proper edits have been made, ensuring that the corrected genome is passed on to specialized cells. Typically, experiments require control tests, but replicating stem cell generated environments can be difficult. Alleviating that problem, CRISPR normalizes the genetic variability that existsacross different iPSC cell lines. Additionally, CRISPRi, an application of CRISPR technology that silences genes instead of editing them, can reach efficiency levels of up to 95% in stem cells!
- Lower-Barriers to Entry: The number of scientific publications has increased because barriers to using genome-editing have decreased. A young research scientist faces a negligible learning curve and can be up and running in a week when choosing to use CRISPR technology . In fact, 51% of new CRISPR users are research scientists using the tool on stem cells for therapeutic purposes, as shown in Figure 4.
Ultimately, CRISPR edited iPSCs should unlock the code to human disease at a cellular level. Three public CRISPR companies are in a good position for the impending stem cell revolution. Editas Medicine EDIT signed a stem cell pact with Glaxo-Smith Kline GSK and Biogen BIIB for next-gen stem-cell therapies; CRISPR Therapeutics CRSP licensed a CRISPR delivery mechanism for blood stem cells and has formed a CRISPR joint venture with Bayer BAYRY; and Intellia Therapeutics NTLA has partnered with biotech giant Novartis NVS to focus on stem-cell based therapies.    These companies, among others, finally might unleash the limitless possibilities that stem cells once promised in regenerative medicine, extending human life spans considerably.
 The Weissman Lab at Stanford University first isolated hematopoietic (blood) stem cells from mice bone marrow in 1988; it would be another decade before human stem cells were isolated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2574516/
The information provided is for informational purposes only. It does not constitute any form of advice or recommendation to buy or sell any securities mentioned. It is intended only to provide observations and views of the author(s) at the time of writing, both of which are subject to change at any time without prior notice. Certain of the statements contained herein are statements of future expectations and other forward-looking statements that are based on ARK's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Past performance is no guarantee of future results. Equities may decline in value due to both real and perceived general market, economic, and industry conditions. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.